WeVote

Bill

Bill

LD 729

Resolve, Regarding Legislative Review Of Chapter 800: Uniform Reporting Of Wholesale Acquisition Costs For Insulin, A Major Substantive Rule Of The Maine Health Data Organization

132nd Legislature (2025-2026) Introduced by Kristi Mathieson

Maine legislature reviews health data organization's insulin wholesale cost reporting rule to ensure pricing transparency and regulatory compliance.

Signed by Governor
0
WeVote Research Nonpartisan
Bill Summary · LD 729

Legislative bill overview

LD 729 is a legislative review resolve that addresses Chapter 800 of the Maine Health Data Organization's rules, which mandates uniform reporting of wholesale acquisition costs (WAC) for insulin products. The bill formally reviews this "major substantive rule" through Maine's legislative review process, which requires certain significant administrative rules to receive legislative approval or oversight.

Why is this important

Insulin pricing and cost transparency directly affect patients' medication access and affordability. By subjecting the Maine Health Data Organization's insulin WAC reporting rule to legislative review, this process ensures transparency in drug pricing data collection and may influence how insulin costs are tracked and potentially regulated in Maine. The quick passage and gubernatorial signature suggest cross-partisan support for insulin pricing oversight.

Potential points of contention

  • Scope of legislative authority: Whether the legislature should routinely review administrative health data rules versus allowing regulatory agencies greater autonomy
  • Practical effectiveness: Whether uniform WAC reporting actually reduces insulin prices for consumers or primarily creates reporting requirements for manufacturers
  • Rule adequacy: Disagreement over whether Chapter 800's current provisions sufficiently address insulin affordability or if stricter price controls should be added

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.